Does US need another expedited development pathway? Groups weigh in
This article was originally published in SRA
Executive Summary
US regulators have had a mixed response to a new pathway they have proposed for expediting the development of medicines intended to treat serious or life-threatening conditions with unmet medical needs. Under the pathway, the Food and Drug Administration would permit manufacturers to take a streamlined approach with shorter studies using smaller patient populations1,2.